Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 131

1.

The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).

Golding B, Luu A, Jones R, Viloria-Petit AM.

Mol Cancer. 2018 Feb 19;17(1):52. doi: 10.1186/s12943-018-0810-4. Review.

2.

Role and targeting of anaplastic lymphoma kinase in cancer.

Della Corte CM, Viscardi G, Di Liello R, Fasano M, Martinelli E, Troiani T, Ciardiello F, Morgillo F.

Mol Cancer. 2018 Feb 19;17(1):30. doi: 10.1186/s12943-018-0776-2. Review.

3.

Treatment After First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small-Cell Lung Cancer.

Kazaz SN, Öztop İ.

Turk Thorac J. 2017 Jul;18(3):66-71. doi: 10.5152/TurkThoracJ.2017.16042. Epub 2017 Jul 1. Review.

4.

The role of brigatinib in crizotinib-resistant non-small cell lung cancer.

Mezquita L, Planchard D.

Cancer Manag Res. 2018 Jan 18;10:123-130. doi: 10.2147/CMAR.S129963. eCollection 2018. Review.

5.

Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared.

Manicone M, Scaini MC, Rodriquenz MG, Facchinetti A, Tartarone A, Aieta M, Zamarchi R, Rossi E.

J Thorac Dis. 2017 Oct;9(Suppl 13):S1391-S1396. doi: 10.21037/jtd.2017.08.151. Review.

6.

Ceritinib -- Benefit Assessment According to §35a Social Code Book V [Internet].

Institute for Quality and Efficiency in Health Care.

Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2015 Sep 29.

7.

Crizotinib (New Therapeutic Indication) -- Benefit Assessment According to §35a Social Code Book V [Internet].

Institute for Quality and Efficiency in Health Care.

Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2016 Mar 30.

8.

Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers.

Alshareef A.

Cancers (Basel). 2017 Oct 28;9(11). pii: E148. doi: 10.3390/cancers9110148. Review.

9.
10.

Targeting MET in cancer therapy.

Mo HN, Liu P.

Chronic Dis Transl Med. 2017 Jul 19;3(3):148-153. doi: 10.1016/j.cdtm.2017.06.002. eCollection 2017 Sep. Review.

11.

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib.

Muller IB, de Langen AJ, Giovannetti E, Peters GJ.

Onco Targets Ther. 2017 Sep 13;10:4535-4541. doi: 10.2147/OTT.S109493. eCollection 2017. Review.

12.

Anaplastic Lymphoma Kinase in Cutaneous Malignancies.

Cao S, Nambudiri VE.

Cancers (Basel). 2017 Sep 12;9(9). pii: E123. doi: 10.3390/cancers9090123. Review.

13.

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.

Santarpia M, Daffinà MG, D'Aveni A, Marabello G, Liguori A, Giovannetti E, Karachaliou N, Gonzalez Cao M, Rosell R, Altavilla G.

Drug Des Devel Ther. 2017 Jul 5;11:2047-2063. doi: 10.2147/DDDT.S113500. eCollection 2017. Review.

14.

Addendum to Commission A12-15 (Crizotinib) [Internet].

Institute for Quality and Efficiency in Health Care.

Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2013 Apr 15.

15.
16.

Non-small cell lung cancer - mutations, targeted and combination therapy.

Kutkowska J, Porębska I, Rapak A.

Postepy Hig Med Dosw (Online). 2017 May 17;71(0):431-445. Review.

17.

[Recent Advances and Prospect of Advanced Non-small Cell Lung Cancer Targeted 
Therapy: Focus on Small Molecular Tyrosine Kinase Inhibitors].

Zhang G, Wang H, Ma Z.

Zhongguo Fei Ai Za Zhi. 2017 Apr 20;20(4):278-286. doi: 10.3779/j.issn.1009-3419.2017.04.09. Review. Chinese.

18.

The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers.

Sabari JK, Santini FC, Schram AM, Bergagnini I, Chen R, Mrad C, Lai WV, Arbour KC, Drilon A.

Onco Targets Ther. 2017 Apr 6;10:1983-1992. doi: 10.2147/OTT.S109295. eCollection 2017. Review.

19.

The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.

Mok TSK, Crino L, Felip E, Salgia R, De Pas T, Tan DSW, Chow LQM.

Cancer Treat Rev. 2017 Apr;55:181-189. doi: 10.1016/j.ctrv.2017.03.006. Epub 2017 Mar 30. Review.

20.

Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib.

Corrales L, Nogueira A, Passiglia F, Listi A, Caglevic C, Giallombardo M, Raez L, Santos E, Rolfo C.

Front Med (Lausanne). 2017 Feb 28;4:13. doi: 10.3389/fmed.2017.00013. eCollection 2017. Review.

Supplemental Content

Loading ...
Support Center